Raymond James Financial Services Advisors, Inc. Oncocyte Corp Transaction History

Raymond James Financial Services Advisors, Inc.

  • $73.5 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 14, 2023
SELL
$0.2 - $0.49 $400 - $980
-2,000 Reduced 11.92%
14,776 $5,000
Q1 2022

May 11, 2022
BUY
$1.15 - $2.25 $19,292 - $37,746
16,776 New
16,776 $25,000
Q4 2021

Feb 08, 2022
SELL
$2.04 - $3.59 $32,127 - $56,538
-15,749 Closed
0 $0
Q3 2021

Nov 02, 2021
BUY
$3.53 - $5.89 $55,593 - $92,761
15,749 New
15,749 $56,000

Others Institutions Holding OCX

# of Institutions
3
Shares Held
411K
Call Options Held
0
Put Options Held
0
View Full List

About Oncocyte Corp

OCX Quotes by TradingView
  • Ticker OCX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 118,609,000
  • Market Cap $294M
  • Description
  • OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....
More about OCX
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email